Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Perspectives on Exertional Rhabdomyolysis.

Rawson ES, Clarkson PM, Tarnopolsky MA.

Sports Med. 2017 Mar;47(Suppl 1):33-49. doi: 10.1007/s40279-017-0689-z. Review.

2.

McArdle Disease Misdiagnosed as Meningitis.

Scalco RS, Chatfield S, Junejo MH, Booth S, Pattni J, Godfrey R, Quinlivan R.

Am J Case Rep. 2016 Nov 30;17:905-908.

3.

Myophosphorylase deficiency (McArdle disease) in a patient with normal pregnancy and normal pregnancy outcome.

Giles W, Maher C.

Obstet Med. 2011 Sep;4(3):120-1. doi: 10.1258/om.2011.100015. Epub 2011 Jul 26.

4.

Sodium valproate increases the brain isoform of glycogen phosphorylase: looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro.

de Luna N, Brull A, Guiu JM, Lucia A, Martin MA, Arenas J, Martí R, Andreu AL, Pinós T.

Dis Model Mech. 2015 May;8(5):467-72. doi: 10.1242/dmm.020230. Epub 2015 Mar 11.

5.

Six-Digit CPK and Mildly Affected Renal Function in McArdle Disease.

Spyropoulos G, Kratimenos P, Mcinnes AD, DeGroote RJ, Koutroulis I.

Case Rep Pediatr. 2014;2014:704398. doi: 10.1155/2014/704398. Epub 2014 Oct 9.

6.

McArdle Disease and Exercise Physiology.

Kitaoka Y.

Biology (Basel). 2014 Feb 25;3(1):157-66. doi: 10.3390/biology3010157.

7.

Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.

Ørngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P.

Neurology. 2014 Feb 18;82(7):607-13. doi: 10.1212/WNL.0000000000000118. Epub 2014 Jan 22.

8.

McArdle disease: a case report and review.

Leite A, Oliveira N, Rocha M.

Int Med Case Rep J. 2012 Jan 20;5:1-4. doi: 10.2147/IMCRJ.S28664. Print 2012.

9.

A transcriptomic approach to search for novel phenotypic regulators in McArdle disease.

Nogales-Gadea G, Consuegra-García I, Rubio JC, Arenas J, Cuadros M, Camara Y, Torres-Torronteras J, Fiuza-Luces C, Lucia A, Martín MA, García-Arumí E, Andreu AL.

PLoS One. 2012;7(2):e31718. doi: 10.1371/journal.pone.0031718. Epub 2012 Feb 9.

10.

A diagnostic algorithm for metabolic myopathies.

Berardo A, DiMauro S, Hirano M.

Curr Neurol Neurosci Rep. 2010 Mar;10(2):118-26. doi: 10.1007/s11910-010-0096-4. Review.

11.

Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor.

Martinuzzi A, Liava A, Trevisi E, Antoniazzi L, Frare M.

Acta Myol. 2007 Jul;26(1):64-6. No abstract available.

13.

Pharmacological and nutritional treatment trials in McArdle disease.

Quinlivan RM, Beynon RJ.

Acta Myol. 2007 Jul;26(1):58-60. Review.

14.

Muscle glycogenoses: an overview.

Di Mauro S.

Acta Myol. 2007 Jul;26(1):35-41. Review. No abstract available.

15.

Can patients with McArdle's disease run?

Pérez M, Moran M, Cardona C, Maté-Muñoz JL, Rubio JC, Andreu AL, Martin MA, Arenas J, Lucia A.

Br J Sports Med. 2007 Jan;41(1):53-4. Epub 2006 Sep 25.

16.

Exercise capacity in a 78 year old patient with McArdle's disease: it is never too late to start exercising.

Perez M, Martin MA, Rubio JC, Maté-Muñoz JL, Gómez-Gallego F, Foster C, Andreu AL, Arenas J, Lucia A, Fleck SJ.

Br J Sports Med. 2006 Aug;40(8):725-6; discussion 726.

17.

An acute decrease in TCA cycle intermediates does not affect aerobic energy delivery in contracting rat skeletal muscle.

Dawson KD, Baker DJ, Greenhaff PL, Gibala MJ.

J Physiol. 2005 Jun 1;565(Pt 2):637-43. Epub 2005 Mar 31.

18.

Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Huerta-Alardín AL, Varon J, Marik PE.

Crit Care. 2005 Apr;9(2):158-69. Epub 2004 Oct 20. Review.

Supplemental Content

Support Center